HLS Therapeutics Inc. (HLTRF)

USD 2.96

(0.0%)

Annual Income Statements

(In USD)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue 63.07 Million 61.46 Million 60 Million 56.1 Million 54.16 Million 61.41 Million
Cost of Revenue 40.28 Million 4.98 Million 3.97 Million 3.62 Million 1.93 Million 2.59 Million
Gross Profit 22.78 Million 56.48 Million 56.03 Million 52.48 Million 52.22 Million 58.82 Million
Operating Expenses 34.48 Million 69.98 Million 62.32 Million 64.57 Million 56.85 Million 51.18 Million
Selling, General and Administrative Expenses 28.28 Million 35.58 Million 32.05 Million 31.38 Million 24.34 Million 18.78 Million
Research and Development Expenses - - - - - -
Other Expenses 27.16 Million - - 509 Thousand - -
Cost and Expenses 74.76 Million 74.96 Million 66.29 Million 68.19 Million 58.78 Million 53.77 Million
Operating Income -10.34 Million -13.44 Million -6.28 Million -12.08 Million -4.62 Million 7.63 Million
Interest Expense 8.74 Million 7.31 Million 6.95 Million 6.3 Million 7.69 Million 17.11 Million
Income Tax Expense -272 Thousand -124 Thousand 1.3 Million -968 Thousand -911 Thousand -3.99 Million
Earnings before Tax -27.8 Million -23.72 Million -11.8 Million -16.29 Million -20.46 Million -28.8 Million
Net Income -27.53 Million -23.59 Million -13.11 Million -15.33 Million -19.55 Million -24.8 Million
Earnings Per Share Basic -0.85 -0.73 -0.41 -0.48 -0.67 -0.92
Earnings Per Share Diluted -0.85 -0.73 -0.41 -0.48 -0.67 -0.92
Weighted Average Shares Outstanding 32.26 Million 32.43 Million 32.18 Million 31.71 Million 29.36 Million 26.95 Million
Weighted Average Shares Outstanding (Diluted) 32.26 Million 32.43 Million 32.18 Million 31.71 Million 29.36 Million 26.95 Million
Gross Margin 0.36 0.92 0.93 0.94 0.96 0.96
EBIT Margin 0.21 0.34 0.40 0.39 0.53 0.35
Profit Margin -0.44 -0.38 -0.22 -0.27 -0.36 -0.40
EBITDA 13.12 Million 17.28 Million 25.18 Million 24.41 Million 20.2 Million 37.63 Million
Earnings Before Tax Margin -0.16 -0.22 -0.10 -0.22 -0.09 0.12

Income Statement Charts